8-K: DaVita Inc. Announces Strong Finish to 2024 with Q4 Results

DaVita Inc. reports its fourth quarter and full year 2024 financial results, highlighting revenue, earnings, and share repurchase activity.

Summary

• DaVita Inc. announced its financial and operating results for the quarter and year ended December 31, 2024.
• Consolidated revenues were $3.295 billion for the quarter and $12.816 billion for the year.
• Operating income was $565 million for the quarter and $2.090 billion for the year.
• Adjusted operating income was $491 million for the quarter and $1.981 billion for the year.
• Diluted earnings per share was $3.09 for the quarter and $10.73 for the year.
• Adjusted diluted earnings per share was $2.24 for the quarter and $9.68 for the year.
• Operating cash flow was $548 million for the quarter and $2.022 billion for the year.
• Free cash flow was $281 million for the quarter and $1.162 billion for the year.
• The company repurchased 2.3 million shares at an average price of $156.46 per share during the quarter.
• For the full year, DaVita repurchased 9.8 million shares at an average price of $140.06 per share.
• Total U.S. dialysis treatments for the fourth quarter of 2024 were 7,278,605, averaging 91,786 treatments per day, a 1.4% decrease compared to the previous quarter.
• Normalized non-acquired treatment growth in the fourth quarter of 2024 compared to the fourth quarter of 2023 was (0.3)%.
• As of December 31, 2024, DaVita provided dialysis services to approximately 281,100 patients at 3,166 outpatient dialysis centers.
• Of these, 2,657 centers were in the U.S. and 509 were in 13 countries outside the U.S..
• The company had approximately 70,400 patients in risk-based integrated care arrangements, representing approximately $5.5 billion in annualized medical spend.
• DaVita's 2025 guidance includes adjusted operating income between $2.010 billion and $2.160 billion, adjusted diluted net income per share between $10.20 and $11.30, and free cash flow between $1.000 billion and $1.250 billion.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong finish to 2024 and the optimistic outlook for 2025, balanced by some concerns about treatment volume decreases and center closure costs.

Positives

• DaVita finished 2024 strong, producing full year adjusted operating income and adjusted EPS in the top half of their guidance range.
• The company repurchased a significant number of shares, returning capital to shareholders.
• DaVita has a substantial number of patients in risk-based integrated care arrangements, indicating a focus on value-based care.
• The company's 2025 guidance projects solid adjusted operating income, adjusted diluted net income per share, and free cash flow.

Negatives

• U.S. dialysis treatments per day decreased by 1.4% compared to the third quarter of 2024.
• Normalized non-acquired treatment growth in the fourth quarter of 2024 compared to the fourth quarter of 2023 was (0.3)%.
• The company incurred charges for U.S. dialysis center closures of approximately $24.2 million and $72.4 million for the three and twelve months ended December 31, 2024, respectively.

Risks

• The company's forward-looking measures involve significant known and unknown risks and uncertainties.
• Actual results may vary materially from these forward-looking measures.
• External conditions, including economic, marketplace, and global health conditions, could impact results.
• Changes in laws, regulations, or requirements applicable to DaVita could affect coverage or reimbursement rates.
• The company relies on significant suppliers, service providers, and other third-party vendors.
• DaVita's ability to attract, retain, and motivate teammates is crucial.
• The company faces increased competition from dialysis providers and others.
• The company's cash flows are variable.

Future Outlook

DaVita's 2025 guidance includes adjusted operating income between $2.010 billion and $2.160 billion, adjusted diluted net income per share between $10.20 and $11.30, and free cash flow between $1.000 billion and $1.250 billion.

Management Comments

• Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range, said Javier Rodriquez, CEO of DaVita Inc.
• As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system.

Industry Context

The report provides insights into the performance of a major player in the dialysis services industry, reflecting trends in revenue, treatment volumes, and cost management within the context of the broader healthcare landscape.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To compare DaVita's performance, one would need to analyze the results of competitors like Fresenius Medical Care, as well as industry benchmarks for treatment costs, revenue per treatment, and operating margins.
• Additionally, comparing DaVita's integrated kidney care metrics to other value-based care providers would offer further context.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and share repurchase program.
• Patients will be impacted by the company's efforts to improve clinical outcomes and quality of life.
• Employees will be impacted by the company's focus on enhancing the teammate experience.
• The healthcare system will be impacted by DaVita's efforts to be a force for positive change.

Next Steps

• DaVita will continue to focus on improving clinical outcomes and enhancing the quality of life for patients and teammates.
• The company will continue to monitor and respond to external conditions and changes in the healthcare landscape.
• DaVita will continue to execute its stock repurchase program.

Key Dates

Keywords

DaVita, dialysis, financial results, operating income, revenue, EPS, share repurchase, integrated kidney care, free cash flow, guidance